Literature DB >> 10552086

Value of the first serum thyroglobulin level after total thyroidectomy for the diagnosis of metastases from differentiated thyroid carcinoma.

G Ronga1, M Filesi, G Ventroni, A R Vestri, A Signore.   

Abstract

The aim of this study was to evaluate the diagnostic significance of the first serum thyroglobulin (Tg) measurement, performed 40 days after total thyroidectomy for differentiated thyroid carcinoma and prior to the ablation of residual thyroid tissue by means of iodine-131 therapy. In a retrospective study we examined 334 consecutive patients followed up for 4-16 years by means of regular Tg measurements, (131)I whole-body scans (WBS) and other diagnostic techniques, if necessary. In 79 patients metastases were discovered (32 lymph node and 47 distant metastases) within 18 months following thyroidectomy. Mean values of first Tg were significantly higher in patients with than in patients without metastases (258.9+/-310.6 vs 15.9+/-19.6 ng/ml; P<0.0001). Receiver operating characteristic (ROC) curve analysis of data revealed that for first Tg values higher than 69.7 ng/ml, the positive predictive value for the presence of metastases exceeded 90%. No statistically significant correlation was found between first Tg value and either thyroid-stimulating hormone (TSH) value or percentage of (131)I uptake by residual thyroid tissue. No other parameter (age, histological type, site of metastases, (131)I uptake by metastases) was significantly related to the first Tg value. We conclude that the first Tg measurement after total thyroidectomy provides a useful early diagnostic indication of metastatic disease in spite of the presence of a post-surgical thyroid remnant, and that this holds true regardless of the TSH value and WBS result. This early information is of clinical relevance for patient follow-up.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10552086     DOI: 10.1007/s002590050477

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  16 in total

1.  Usefulness of repeated recombinant human thyrotropin-stimulated thyroglobulin test in the post-surgical follow-up of very low-risk patients with differentiated thyroid carcinoma.

Authors:  C Cappelli; M Rotondi; I Pirola; E De Martino; E Gandossi; B Agosti; E Agabiti Rosei; L Chiovato; M Castellano
Journal:  J Endocrinol Invest       Date:  2011-11-07       Impact factor: 4.256

Review 2.  Papillary thyroid cancer: medical management and follow-up.

Authors:  Richard T Kloos
Journal:  Curr Treat Options Oncol       Date:  2005-07

3.  A low thyroglobulin level cannot be used to avoid adjuvant 131I therapy after thyroidectomy for thyroid carcinoma.

Authors:  Paolo Zanotti-Fregonara; Gaia Grassetto; Elif Hindié; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02       Impact factor: 9.236

4.  Limited clinical value of periablative changes of serum markers in the prediction of biochemical remission in patients with papillary thyroid cancer.

Authors:  Heeyoung Kim; Seong-Jang Kim; In-Joo Kim; Keunyoung Kim; Sojung Kim; Bo Hyun Kim; Sang Soo Kim; Jeon Yoon Kyung
Journal:  Nucl Med Mol Imaging       Date:  2013-08-21

5.  Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma.

Authors:  Hee Jeong Park; Geum-Cheol Jeong; Seong Young Kwon; Jung-Joon Min; Hee-Seung Bom; Ki Seong Park; Sang-Geon Cho; Sae-Ryung Kang; Jahae Kim; Ho-Chun Song; Ari Chong; Su Woong Yoo
Journal:  Nucl Med Mol Imaging       Date:  2014-06-28

Review 6.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

7.  Prognostic value of an increase in the serum thyroglobulin level at the time of the first ablative radioiodine treatment in patients with differentiated thyroid cancer.

Authors:  Marie-Odile Bernier; Olivier Morel; Patrice Rodien; Jean-Pierre Muratet; Philippe Giraud; Vincent Rohmer; Christian Jeanguillaume; Jean-Claude Bigorgne; Pierre Jallet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-26       Impact factor: 9.236

8.  Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.

Authors:  N Lima; H Cavaliere; E Tomimori; M Knobel; G Medeiros-Neto
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

9.  Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer.

Authors:  A Piccardo; F Arecco; S Morbelli; P Bianchi; F Barbera; M Finessi; S Corvisieri; E Pestarino; L Foppiani; G Villavecchia; M Cabria; F Orlandi
Journal:  J Endocrinol Invest       Date:  2009-07-28       Impact factor: 4.256

10.  Recurrent/metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans.

Authors:  Eun-Kyung Park; June-Key Chung; Il Han Lim; Do Joon Park; Dong Soo Lee; Myung Chul Lee; Bo Youn Cho
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-09       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.